Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

223.12USD
26 May 2017
Change (% chg)

$-1.24 (-0.55%)
Prev Close
$224.36
Open
$224.41
Day's High
$225.14
Day's Low
$222.95
Volume
1,697,663
Avg. Vol
2,875,329
52-wk High
$261.27
52-wk Low
$184.50

Latest Key Developments (Source: Significant Developments)

Allergan announces closing of public offering
Friday, 26 May 2017 07:00am EDT 

May 26 (Reuters) - Allergan Plc ::Allergan announces closing of public offering of senior notes to refinance existing debt.  Full Article

Allergan prices public offering of senior notes to refinance existing debt
Tuesday, 23 May 2017 05:30pm EDT 

May 23 (Reuters) - Allergan Plc :Allergan announces pricing of public offering of senior notes to refinance existing debt.Allergan plc - has priced an offering of eur 2.7 billion aggregate principal amount of senior unsecured notes in 4 tranches.Allergan plc - notes will be issued by its indirect wholly-owned subsidiary, allergan funding scs.  Full Article

Carl Icahn dissolves shared share stake in Allergan
Monday, 15 May 2017 05:59pm EDT 

May 15 (Reuters) - Carl Icahn::Carl Icahn dissolves share stake in Allergan Plc - sec filing.Carl Icahn takes shared share stake of 10.6 million shares in Welbilt Inc.Carl Icahn holdings cited is Icahn's shared share stake in the respective companies.Carl Icahn - change in holdings are as of March 31, 2017 and compared with the previous quarter ended as of Dec 31, 2016.  Full Article

Appaloosa LP takes share stake in CBS, cuts in Allergan
Friday, 12 May 2017 04:30pm EDT 

May 12 (Reuters) - Appaloosa LP:Appaloosa lp takes share stake of 1.0 million of class b shares in cbs corp.Appaloosa lp cuts share stake in allergan plc by 31.1 percent to 2.9 million.Appaloosa lp - change in holdings are as of march 31, 2017 and compared with the previous quarter ended as of dec 31, 2016.  Full Article

Allergan announces proposed public offering of senior notes to refinance existing debt
Wednesday, 10 May 2017 03:00am EDT 

May 10 (Reuters) - Allergan Plc :Allergan announces proposed public offering of senior notes to refinance existing debt.Expects to commence an offering of euro-denominated senior unsecured notes in multiple tranches in coming weeks.Allergan - will be allergan's debut bond issuance in euro bond market and is intended to be an economic hedge of company's increasing euro revenues.  Full Article

Allergan reports qtrly loss per share from continuing operations of $7.85
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Allergan Plc ::Allergan reports solid start to 2017 with 5 pct increase in first quarter GAAP net revenues to $3.6 billion.Q1 non-GAAP earnings per share $3.35 .Q1 revenue $3.6 billion versus I/B/E/S view $3.54 billion.Qtrly loss per share from continuing operations $7.85.Sees FY total net revenues $15,800 – $16,000 million.Company raises full year 2017 guidance.Sees FY net loss per share $9.70 - $10.20.Sees FY research and development expense to be about $2.1 billion.Sees 2017 non-GAAP net income per share $15.85 - $16.35.FY2017 earnings per share view $16.05, revenue view $15.73 billion -- Thomson Reuters I/B/E/S.Q1 earnings per share view $3.30 -- Thomson Reuters I/B/E/S.  Full Article

Allergan partners with Target Pharmasolutions to advance NASH research
Thursday, 20 Apr 2017 09:00am EDT 

April 20 (Reuters) - Allergan Plc :Allergan partners with Target Pharmasolutions to advance NASH research.Allergan-Target-Nash is 5-year longitudinal observational study, looks at patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.  Full Article

Argentum Pharmaceuticals, Allergan settle patent dispute over Restasis
Tuesday, 18 Apr 2017 04:01pm EDT 

April 18 (Reuters) - Allergan Plc :Argentum PHARMACEUTICALS and Allergan settle patent dispute over Restasis.Argentum Pharmaceuticals - specific date on which Argentum may launch generic product and other details concerning settlement have not been disclosed.Argentum Pharmaceuticals- agreement generally provides Argentum may commence marketing generic equivalent product sometime prior to expiration of patents covering Restasis.  Full Article

Prospect Park Capital says will not receive milestone payment held onto upon sale of interest in IOI
Wednesday, 29 Mar 2017 12:43pm EDT 

Prospect Park Capital Corp : Says advised by Serenity Pharmaceuticals co will not receive milestone payment which it held onto upon sale of interest in IOI . Says prospect park's final return on its investment in IOI remains at 8%. .Will not receive payment in light of Allergan exercising unilateral right to terminate license, transfer, development agreement with Serenity.  Full Article

Allergan and Paratek announce positive results from two phase 3 trials of sarecycline
Monday, 27 Mar 2017 07:31am EDT 

Allergan Plc : Allergan and Paratek announce positive results from two phase 3 trials of sarecycline for the treatment of moderate to severe acne . Allergan Plc - plans to file a new drug application (NDA) to U.S. Food & drug administration (fda) in second half of this year . On track for FDA submission in second half of 2017 .Sarecycline was statistically significantly superior to placebo with respect to primary efficacy endpoints.  Full Article

More From Around the Web

BRIEF-Allergan announces closing of public offering

* Allergan announces closing of public offering of senior notes to refinance existing debt Source text for Eikon: Further company coverage: